Mineralocorticoid excess and MR implication in cardiac diseases have extensively been studied the last decade, and the involvement of MR activation in the development of several heart diseases has been demonstrated through the use of specific MR antagonists (spironolactone, eplerenone) in clinical and experimental studies. This evidence concerns the gene NR3C2 and heart disorder.